Skip to main content

Table 4 Incidence of adverse drug reactions

From: Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective study

Adverse drug reactions

Intervention group (n = 31) n (%)

Non-intervention group (n = 39) n (%)

P-value (Any)

Grade

Any

3 ~ 4

Any

3 ~ 4

 

Hand-foot skin reactiona

23(74.2)

2(6.5)

19(48.7)

3(7.7)

0.049*

Diarrhea

21(67.7)

2(6.5)

5(12.8)

1(2.6)

< 0.001**

Hypertension

16(51.6)

6(19.4)

15(38.5)

5(12.5)

0.336

Anorexia

15(48.4)

1(3.2)

6(15.4)

-

0.002**

Hair loss

13(41.9)

-

5(12.8)

-

0.012*

Thrombocytopenia

11(35.5)

2(6.5)

4(10.3)

3(7.7)

0.018*

AST increased

11(35.5)

5(16.1)

6(15.4)

3(7.7)

0.091

Hoarseness

10(32.3)

-

4(10.3)

-

0.034*

ALT increased

9(29.0)

-

6(15.4)

3(7.7)

0.242

Serum amylase increased

9(29.0)

6(19.4)

3(7.7)

1(2.6)

0.026*

Fatigue

7(22.6)

-

1(2.6)

-

0.018*

Stomatitis

6(19.4)

-

1(2.6)

-

0.039*

Hypothyroidism

5(16.1)

-

3(7.7)

-

0.452

Blood bilirubin increased

5(16.1)

1(3.2)

3(7.7)

1(2.6)

0.452

Rash maculo-papular

4(12.9)

-

4(10.3)

-

1.000

  1. aPalmar-plantar erythrodysesthesia syndrome (NCI-CTCAE).
  2. *P < 0.05.
  3. **P < 0.01.